News

Ideas That Generate Results

The ability of Biosimilars to act as growth engines by ensuring broader access to medicines and sustainability is helping biosimilars gain value in emerging economies. Countries such as India, China, Korea, Vietnam and Brazil are witnessing remarkable biosimilar uptake as compared to advanced economies. This surge can be attributed to local policies or the fragmented regulatory framework and “biosimilar” attitude of emerging nations.
 
According to our latest research report, “Global Biosimilar Market Outlook 2018”, although the current biosimilars market is small, the future looks optimistic due to the immense government support for the industry. Emerging markets will play the role of a major driver on the biosimilar market. This can be attributed to the local policies and the biosimilar attitude of these regions. The governments in these economies are also the realizing this potential and encouraging the growth of biosimilars by defining clear regulatory pathways for their smooth approval.
 
In our report, we have segmented the biosimilars market into various categories such as EPO, HGH, IFN, mAb, Insulin and G-CSF. Each market has been analyzed in terms of major approved biosimilars, drug pipeline, and the impact of patent expiries of important biologics. Similarly, major geographies are also discussed. The regulatory scenario of all the economies has been presented.
 
At the end, major players based in key economies have been profiled. A brief business overview of these players is given alongwith approved biosimilar products and the ones in the pipeline. Overall, the report will help provide a good understanding of the market and the recent trends that are prevailing.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM657.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm